Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John H Rex

Showing results (1-10 of 95) with videos related to

Pageof 10
Sort By:
Critical Care Medicine|March 22, 2006
Antifungal prophylaxis in the intensive care unit: who should get it?John H Rex
Nature Reviews. Microbiology|September 24, 2004
Staying ahead of the fourth horsemanJohn H Rex
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 19, 2006
Galactomannan and the diagnosis of invasive aspergillosisJohn H Rex
Critical Care Medicine|March 1, 2006
Candida in the peritoneum: passenger or pathogen?John H Rex
Current Opinion in Investigational Drugs (London, England : 2000)|July 2, 2002
Ravuconazole Eisai/Bristol-Myers SquibbSevtap Arikan, John H Rex
Translational Research : the Journal of Laboratory and Clinical Medicine|March 14, 2020
Evaluating for-profit public benefit corporations as an additional structure for antibiotic development and commercializationKevin Outterson, John H Rex
The Lancet. Infectious Diseases|April 3, 2016
Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approachJohn H Rex, Kevin Outterson
Applied Health Economics and Health Policy|February 11, 2023
Global Pull Incentives for Better Antibacterials: The UK Leads the WayKevin Outterson, John H Rex
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 26, 2020
Antibacterial R&D at a Crossroads: We've Pushed as Hard as We Can … Now We Need to Start Pulling!John H Rex, Kevin Outterson
Expert Opinion on Emerging Drugs|July 2, 2005
New agents for the treatment of systemic fungal infections--current statusSevtap Arikan, John H Rex
Pageof 10

Showing results (1-10 of 95) with videos related to

Sort By:
Pageof 10
Critical Care Medicine|March 22, 2006
Antifungal prophylaxis in the intensive care unit: who should get it?John H Rex
Nature Reviews. Microbiology|September 24, 2004
Staying ahead of the fourth horsemanJohn H Rex
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 19, 2006
Galactomannan and the diagnosis of invasive aspergillosisJohn H Rex
Critical Care Medicine|March 1, 2006
Candida in the peritoneum: passenger or pathogen?John H Rex
Current Opinion in Investigational Drugs (London, England : 2000)|July 2, 2002
Ravuconazole Eisai/Bristol-Myers SquibbSevtap Arikan, John H Rex
Translational Research : the Journal of Laboratory and Clinical Medicine|March 14, 2020
Evaluating for-profit public benefit corporations as an additional structure for antibiotic development and commercializationKevin Outterson, John H Rex
The Lancet. Infectious Diseases|April 3, 2016
Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approachJohn H Rex, Kevin Outterson
Applied Health Economics and Health Policy|February 11, 2023
Global Pull Incentives for Better Antibacterials: The UK Leads the WayKevin Outterson, John H Rex
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 26, 2020
Antibacterial R&D at a Crossroads: We've Pushed as Hard as We Can … Now We Need to Start Pulling!John H Rex, Kevin Outterson
Expert Opinion on Emerging Drugs|July 2, 2005
New agents for the treatment of systemic fungal infections--current statusSevtap Arikan, John H Rex
Pageof 10